AXS-05 (dextromethorphan-bupropion)
Phase 3TerminatedDevelopment Stage
Agitation in Patients With Dementia of the Alzheimer's Type
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Nov 21, 2024 → Apr 25, 2025
About AXS-05 (dextromethorphan-bupropion)
AXS-05 (dextromethorphan-bupropion) is a phase 3 stage product being developed by Axsome Therapeutics for Agitation in Patients With Dementia of the Alzheimer's Type. The current trial status is terminated. This product is registered under clinical trial identifier NCT06736509. Target conditions include Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor.
What happened to similar drugs?
2 of 13 similar drugs in Agitation in Patients With Dementia of the Alzheimer's Type were approved
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06736509 | Phase 3 | Terminated |
| NCT04634669 | Phase 2 | Terminated |
Competing Products
20 competing products in Agitation in Patients With Dementia of the Alzheimer's Type